InterGenetics Uses Genomics

Click here to view chart with audio.
Flash 6 player or higher required. Click Here to download Flash Player.


Because all cancer has some genetic basis for development, researching
the genetic basis of this disease allows us to find gene combinations
that are predictive of developing cancer, such that many of these genes
or gene products can also become drug leads or targeted therapy for
treating specific types of cancer.

InterGenetics® scientists have discovered a complex algorithm of
multiple gene combinations related to breast cancer and other cancers
by testing more than a million combinations of genes. This breakthrough
discovery is an accurate method of predicting the risk of developing
breast cancer and other cancers and has application in other disease
processes and preventative medicines.

The OncoVue® Breast Cancer Risk score is calculated at three life
states - pre-menopause, peri-menopause, and post-menopause - by
analyzing a patient's individual results as compared to all other women
tested using proprietary algorithms to determine their unique level of
risk. The genetic analysis process of this information is extremely
accurate (>99.999%). OncoVue® scores are an assessment based upon
the current knowledge of genes contributing to a unique risk level.

This test involves Polymerase Chain Reaction (PCR). This service is
performed pursuant to an agreement with Roche Molecular System, Inc.